Phase II results from trials of the anticoagulant rivaroxaban (Xarelto) are promising in showing that it may reduce major ischaemic events like death, MI and stroke post acute coronary syndrome. A dose-dependent increase in clinically significant bleeding occurred so ongoing trials are required to outweigh benefits associated with this risk.
저작권자 © 메디칼업저버 무단전재 및 재배포 금지